Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer

14 Jun 2021
Severyn Ferneza, Markiyan Fetsych, Roman Shuliak, Halyna Makukh, Natalia Volodko, Roman Yarema, Tara Fetsych

Ovarian cancer (OC) represents the most lethal malignancy in gynaecologic oncology practice and shows a high recurrence rate due to its early chemoresistance to first-line chemotherapy. Yet, timely selection of the correct treatment strategy is likely to prolong a patient’s survival. MicroRNAs (miRNAs) are a class of short non-coding RNAs responsible for the expression of 30%–60% of human genes. In numerous studies, miRNAs have been used to provide the overall prognosis for patients and analyse the process’s prevalence and responses to chemotherapy. In particular, miRNAs as markers for predicting the sensitivity of OC to platinum- and taxane-based chemotherapeutics can significantly improve the treatment efficacy. This article highlights two families of miRNAs: miR-200 and let-7, which are promising for further research on OC and its chemosensitivity.

Related Articles

Saswata Saha, Vijay M Patil, Vanita Noronha, Nandini Menon, Ajay Kumar Singh, Mannavi Suman, Amit Agrawal, Satvik Khaddar, Shatabdi Chakraborty, Prathamesh S Pai, Devendra A Chaukar, Pankaj Chaturvedi, Sarbani Ghosh Laskar, Kumar Prabhash
Ghazal Tansir, Sameer Rastogi, Sravan Kumar Dubasi, Sindhu Chitikela, Lavu Rohit Reddy, Adarsh Barwad, Ankur Goyal
Steve Joseph Benny, Jeffrey Mathew Boby, Ravindran Chirukandath, Togy Thomas, Ambika Vazhuthakat, Edwin Saji, Athul Raj Raju, Aju Mathew
Tabassum Wadasadawala, Roshankumar Patil, Johnny Carlton, Shalini Verma, Namita Umesh, Pallavi Rane, Rajiv Sarin, Rima Pathak, Jyoti Bajpai, Nita Nair, Tanuja Shet, Ramneet Kaur